#Modular Biomanufacturing

[cihealthinsightshub]

Sustainable Bioprocessing Gains Ground with Recyclable Single-Use Systems

The Single-use Bioprocessing Market is entering a transformative growth phase, fueled by the rapid expansion of biopharmaceutical manufacturing, rising demand for flexible production systems, and heightened focus on contamination control. Valued at USD 7.62 billion in 2021, the market is projected to reach USD 25.40 billion by 2031, growing at an impressive CAGR of 18.93% during the forecast period (2024–2031).

Unlock exclusive insights with our detailed sample report :

This market is evolving rapidly with the increasing adoption of single-use bioprocessing systems such as bioreactors, fermenters, mixers, filtration units, bags, and containers. These disposable systems, primarily made of sterilizable plastic components, support critical processes like upstream expression, purification, storage, and separation of biopharmaceutical products. As global biomanufacturing shifts toward agile, cost-effective, and contamination-free solutions, single-use technologies are being embraced by both established pharma giants and emerging biotech firms—especially in alignment with trends seen in the United States and Asia, where scalable, single-use systems are driving next-gen biologics production.

Key Market Drivers

1. Rise in Biologics and Personalized Medicine: The growth of monoclonal antibodies, gene therapy, and personalized medicine has created a strong need for scalable, contamination-free, and faster bioprocessing methods. Single-use systems (SUS) offer agility and ease of implementation, making them ideal for such advanced therapies.

2. Cost Efficiency and Operational Flexibility: Unlike traditional stainless-steel systems, SUS eliminate the need for cleaning and sterilization, significantly reducing downtime and water/chemical usage. This makes them highly attractive for small-to-mid-sized biotech firms and contract manufacturing organizations (CMOs).

3. Pandemic Preparedness and Vaccine Development: COVID-19 and subsequent global health threats highlighted the urgent need for rapid-response manufacturing capabilities. Single-use systems enabled fast-tracked vaccine production and played a pivotal role in scaling mRNA technologies.

4. Regulatory and Environmental Incentives: The U.S. FDA and EMA support the adoption of single-use bioreactors and modular facilities, facilitating market expansion. Meanwhile, vendors are innovating biodegradable materials to tackle concerns over plastic waste and sustainability.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements:

Market Segmentation Snapshot

By Product Type: The market is segmented into bioreactors, mixers, bags, tubes & connectors, sampling systems, and others. Bioreactors and mixing systems account for the largest share due to their central role in upstream processing.

By Workflow: Upstream processing dominates the market share, given the high usage of SUS in cell culture and fermentation.

By End-User: Biopharmaceutical companies hold the majority share, followed by CMOs and academic research institutes.

Regional Insights

United States: The U.S. remains the largest and most mature market, fueled by robust biopharma R&D, government funding, and large-scale manufacturing investments. In 2024, the U.S. government announced a new initiative to strengthen domestic biologics production, allocating over USD 2 billion toward advanced manufacturing platforms—predominantly single-use facilities. Leading companies like Thermo Fisher Scientific, Danaher Corporation, and Sartorius Stedim Biotech are expanding their manufacturing capacities across North America.

Japan: Japan’s biopharma industry is rapidly integrating single-use systems as part of its strategic vision for regenerative medicine and mRNA vaccine production. In 2024, the Japanese Ministry of Health, Labour and Welfare (MHLW) introduced incentives for companies transitioning from conventional systems to disposable solutions. Furthermore, leading Japanese firms such as Asahi Kasei and Nipro Corporation are increasing R&D spending on sustainable single-use materials to enhance product lifecycle management.

Europe and Asia-Pacific: Germany, the UK, and Switzerland continue to be innovation hubs, while emerging economies in the Asia-Pacific region, such as China, South Korea, and India, are rapidly adopting SUS to scale biologics and biosimilars production.

Latest Industry Trends

AI Integration in Bioprocess Monitoring: Vendors are now embedding AI and data analytics into SUS platforms to allow predictive maintenance, batch tracking, and process optimization.

Modular Biomanufacturing Units: Companies are investing in mobile, modular units using SUS to cater to outbreak hotspots and rural regions, enhancing supply chain agility.

Green Bioprocessing Innovations: Environmental concerns are driving innovations in recyclable polymers and closed-loop systems to minimize single-use plastic waste.

M&A Activity on the Rise: The market is witnessing increased mergers and acquisitions. For example, in Q1 2025, Repligen Corporation announced the acquisition of a European tubing and bagging system manufacturer to strengthen its product portfolio.

Buy the exclusive full  report here:

Competitive Landscape

The market is highly competitive and fragmented, with major players focusing on product innovation, capacity expansion, and strategic partnerships. Notable players include:

Thermo Fisher Scientific Inc.

Sartorius AG

Danaher Corporation (Cytiva and Pall)

Merck KGaA

Eppendorf AG

Parker Hannifin Corp.

Avantor, Inc.

Corning Incorporated

PBS Biotech, Inc.

Saint-Gobain Performance Plastics

These companies are investing in next-generation single-use assemblies, automation, and flexible manufacturing to meet evolving industry demands.

Growth Opportunities

CMO & CDMO Expansion: As pharmaceutical outsourcing grows, CMOs are increasingly deploying SUS to reduce turnaround time and manage multiple client processes efficiently.

Biosimilar Production: The patent cliff for blockbuster biologics has opened lucrative opportunities for biosimilars, where SUS offers a cost-effective pathway to scale.

Emerging Markets Penetration: Expansion in Latin America, Southeast Asia, and Africa presents a significant untapped opportunity, supported by international funding agencies.

Regenerative Medicine and Cell Therapy: As cell therapy and tissue engineering progress, single-use bioreactors and closed systems will be pivotal in clinical and commercial scale-up.

Stay informed with the latest industry insights-start your subscription now:

Conclusion

The global single-use bioprocessing market is on the cusp of a revolution, catalyzed by innovation in biologics, operational efficiency, and a growing preference for flexible, scalable manufacturing. The United States and Japan stand at the forefront of this transformation, while global demand signals a sustained, long-term market boom. As regulatory and environmental concerns are addressed through innovation, single-use technologies are poised to become the new standard in biopharmaceutical manufacturing.

[healthcareindustryresearch]

Single Use Assemblies: Catalysts for Transformation in Biomanufacturing and Beyond

The Strategic Imperative Behind Single Use Assemblies

In today’s hyper-competitive biopharmaceutical and advanced manufacturing ecosystems, agility, scalability, and risk mitigation have become the primary strategic levers for success. Single Use Assemblies (SUAs)—pre-sterilized, disposable flow paths customized for specific manufacturing steps—are not merely operational conveniences; they are transformational enablers redefining how organizations think about capital investments, operational efficiency, and regulatory compliance.

Senior decision-makers are increasingly recognizing that the shift toward single use solutions is more than a tactical choice—it's a strategic necessity to future-proof operations against mounting market pressures, supply chain complexities, and regulatory demands. For those poised to lead in the coming decade, the ability to harness Single Use Assemblies will be a defining competitive advantage.

Request Sample Pages

Tangible Applications Driving Immediate Business Value

Across industries, Single Use Assemblies have already demonstrated clear, measurable impact, particularly in biopharma, cell and gene therapy, vaccine production, and biologics manufacturing. Their adoption translates directly into tangible benefits:

Reduced Time-to-Market: By eliminating cleaning validation requirements and streamlining production setup, SUAs allow facilities to transition between products faster—an essential capability when responding to surges in demand or pivoting to new therapeutic areas.

Enhanced Contamination Control: Pre-sterilized and disposable by design, Single Use Assemblies significantly lower the risk of cross-contamination, a critical concern in sensitive biologic processes.

Operational Flexibility: Facilities outfitted with modular, single-use systems can scale production volumes up or down without the lengthy retrofits required by traditional stainless-steel systems.

Lower Capital Expenditure: Instead of massive upfront investments in fixed infrastructure, SUAs offer a pay-as-you-go model that aligns costs more tightly with production cycles.

Global Standardization: Single Use Assemblies facilitate harmonized processes across multiple manufacturing sites, ensuring consistent quality and simplifying global regulatory submissions.

In short, companies that deploy SUAs are better positioned to optimize operational costs, enhance product quality, and respond dynamically to evolving market conditions.

Emerging Trends and Long-Term Industry Shifts

Looking ahead, the role of Single Use Assemblies is poised to expand beyond their current applications, driving long-term transformations across multiple sectors. Several macrotrends are already reshaping the future landscape:

1. The Rise of Personalized Medicine

Personalized therapies, particularly cell and gene therapies, require smaller batch sizes and highly adaptable manufacturing processes. Single Use Assemblies enable the rapid, flexible production setups needed to accommodate the individualized nature of these therapies, opening new revenue streams for manufacturers who can pivot quickly.

2. Digitalization and Smart Manufacturing Integration

Integration of SUAs into digitalized biomanufacturing systems is emerging as a critical focus. Smart sensors embedded within assemblies can provide real-time monitoring of critical process parameters, enabling predictive maintenance, automated quality assurance, and greater process transparency. The convergence of single-use technology and Industry 4.0 principles will drive unprecedented operational intelligence.

3. Sustainability Pressures and Circular Economies

While disposability is a hallmark of SUAs, environmental concerns are prompting manufacturers to innovate in recycling, energy recovery, and sustainable materials. Companies that proactively embed eco-design principles into their single-use strategies will not only meet regulatory expectations but also resonate with increasingly sustainability-conscious stakeholders.

4. Global Expansion of Biomanufacturing Hubs

Emerging markets are accelerating the establishment of local biomanufacturing capabilities to ensure healthcare sovereignty. Single Use Assemblies offer these new facilities a fast, cost-effective pathway to operational readiness without the burden of extensive legacy infrastructure, making them a cornerstone of global healthcare expansion strategies.

5. Advanced Customization and Modular Solutions

Manufacturers are demanding bespoke single-use configurations tailored to highly specific process needs. In response, suppliers are evolving from standard off-the-shelf offerings to highly modular, customizable assemblies that seamlessly integrate with diverse manufacturing platforms.

Business Opportunities and Strategic Transformation Potential

For forward-looking executives, the Single Use Assemblies market represents a multi-faceted opportunity to unlock value and reshape operational paradigms. Strategic avenues worth exploring include:

Investing in Flexible Manufacturing Networks

Single Use Assemblies empower organizations to design flexible manufacturing networks that can quickly reconfigure production lines based on therapeutic needs or regional demand shifts. Companies investing early in flexible infrastructures will achieve superior agility and risk diversification.

Accelerating Facility Design and Time-to-Operation

The traditional model of building massive biomanufacturing facilities over multiple years is giving way to smaller, modular facilities that can come online in a fraction of the time. Leveraging SUAs allows for rapid deployment, significantly reducing the time to revenue generation.

Enhancing Supply Chain Resilience

Single-use technologies simplify supply chain dynamics by reducing dependencies on cleaning chemicals, water systems, and validation labor. They also enable decentralized production models, reducing logistical risks and fostering localized manufacturing ecosystems.

Driving Collaborative Innovation

The complexity and customization potential of Single Use Assemblies open doors to collaborative innovation between manufacturers, equipment providers, and materials scientists. Forward-thinking organizations are forming strategic partnerships to co-develop next-generation single-use solutions tailored to emerging bioprocess needs.

Differentiating Through Quality and Compliance

As regulatory agencies intensify their focus on quality by design (QbD) and risk-based approaches, Single Use Assemblies offer built-in advantages. Pre-validated, closed-system designs contribute directly to compliance readiness, giving companies a strategic edge in regulatory submissions and inspections.

Preparing for the Future: Strategic Considerations for Leaders

Adopting Single Use Assemblies at scale requires deliberate strategy, visionary leadership, and cross-functional collaboration. Executives aiming to maximize the transformational potential of SUAs should consider the following strategic imperatives:

Develop a Clear Single-Use Technology Roadmap: Define long-term goals, assess current capabilities, and map out phased adoption plans that align with business objectives.

Invest in Workforce Upskilling: Equip teams with the skills necessary to design, implement, and manage single-use systems, from operational staff to quality assurance professionals.

Prioritize Supplier Partnerships: Select strategic suppliers who not only deliver reliable assemblies but also offer design expertise, regulatory support, and innovation roadmaps.

Incorporate Sustainability Metrics: Build environmental performance goals into the selection, usage, and disposal processes associated with Single Use Assemblies.

Foster a Culture of Agility: Embrace operational models that allow for rapid decision-making and adaptation to new market realities, supported by the inherent flexibility of single-use systems.

Conclusion: Charting a Visionary Path Forward

Single Use Assemblies are no longer ancillary components of manufacturing; they are strategic assets driving profound shifts in how organizations innovate, produce, and compete. Senior executives and industry leaders who view SUAs through a visionary lens will be best positioned to capture new growth opportunities, mitigate risks, and lead their industries into a future defined by agility, sustainability, and operational excellence.

The era of static, monolithic manufacturing is ending. In its place, a dynamic, flexible, and intelligent future is emerging—and Single Use Assemblies are at the heart of this transformation. Now is the time to act boldly, invest wisely, and embrace the future of manufacturing.

Don’t miss out on business opportunities in Single Use Assemblies Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

[sfoxxlife]

Single Use Assemblies

In the fast-paced world of pharmaceuticals and biotech, efficiency, safety, and innovation are no longer luxuries—they’re necessities. That’s where Single Use Assemblies (SUAs) shine. These pre-assembled, pre-sterilized systems are transforming how drugs are developed and produced, cutting down cleaning time and contamination risks while boosting productivity.

Email Us :  sales@foxxlifesciences.com

Let’s dive into what makes single use assemblies the backbone of modern biomanufacturing—and how foxxlifesciences is leading the charge.

What Are Single Use Assemblies?

At their core, single use assemblies are modular, disposable systems used in bioprocessing. They include components like tubing, filters, connectors, clamps, and bags—all pre-assembled and sterilized for immediate use. No cleaning. No cross-contamination. Just plug, play, and process.

Why Are They Important in Biopharma?

Because time is money—and so is sterility. Single use assemblies cut out lengthy cleaning validations and sterilization steps. This results in quicker batch turnover, fewer errors, and consistent product quality.

Advantages of Single Use Assemblies

Reduced Risk of Contamination

You know that feeling when everything just clicks? That’s the peace of mind SUAs bring. Since they’re sterile and single-use, there's virtually zero chance of cross-contamination.

Faster Turnaround Times

Why waste hours—or days—cleaning stainless steel systems? SUAs arrive ready-to-go. You can switch from one process to another in record time.

Cost-Efficiency

Less downtime = more output. Plus, you save on cleaning agents, labor, and validation testing.

Scalability and Flexibility

Whether you’re running a small clinical trial or a full-scale commercial batch, single use systems scale easily with your needs.

Core Components of Single Use Assemblies

Tubing Systems

Flexible, customizable tubing ensures smooth fluid transfer without leaks or contamination.

Connectors and Clamps

Designed for secure, leak-proof connections that are easy to assemble and disassemble.

Sterile Filters

Essential for removing particulates and microbes to ensure the purity of biopharmaceuticals.

Storage Bags and Containers

From 50 mL to 500 liters, these hold everything from raw ingredients to final formulations.

Applications of Single Use Assemblies

Biopharmaceutical Manufacturing

From fermentation to purification, SUAs cover the full drug development pipeline.

Cell and Gene Therapy

These cutting-edge therapies demand ultra-clean, adaptable systems. SUAs deliver.

Vaccine Production

Speed and sterility are crucial. SUAs allow fast pivots—perfect for pandemic response.

Laboratory and R&D Environments

Save time, stay flexible, and focus on innovation—not equipment cleaning.

foxxlifesciences and Their Role in the Industry

Who Is foxxlifesciences?

A global leader in laboratory and bioprocessing solutions, foxxlifesciences provides high-quality single use technologies that meet the strictest standards.

How foxxlifesciences Innovates in Single Use Solutions

Customization is the name of the game. foxxlifesciences offers tailor-made SUAs to fit your exact process parameters.

Commitment to Quality and Customization

From concept to validation, foxxlifesciences ensures every product meets rigorous ISO and GMP standards.

Comparison With Traditional Stainless-Steel Systems

Environmental Impact

While stainless steel can be reused, the water and energy for cleaning are immense. SUAs reduce that drastically.

Operational Efficiency

SUAs streamline setup, operation, and turnover—cutting delays and maximizing productivity.

Validation and Compliance

Forget days of validation checks. SUAs come with pre-validated documentation that keeps auditors happy.

Common Concerns About Single Use Assemblies

Waste Management

Yes, they’re disposable—but many components are recyclable. foxxlifesciences even supports recycling programs.

Supply Chain Dependence

With proper planning and a reliable vendor like foxxlifesciences, you can mitigate supply hiccups.

Material Compatibility

Top-tier suppliers use pharma-grade plastics tested for chemical compatibility and extractables.

How to Choose the Right Single Use Assemblies

Identify Your Process Needs

Start with your workflow. Where can disposables save time or improve quality?

Evaluate Vendor Capabilities

Look for customization, compliance, and customer support—hello, foxxlifesciences.

Focus on Customization and Quality Assurance

One-size-fits-all doesn’t cut it. Go with assemblies built around your process, not the other way around.

Regulatory Considerations and Compliance

GMP Standards

SUAs must align with Good Manufacturing Practices—built, handled, and documented correctly.

FDA and EMA Guidelines

The FDA and EMA are increasingly supportive of disposables—if they're well-documented and validated.

Documentation and Validation

Choose vendors who offer comprehensive validation packets to simplify audits.

Future of Single Use Technology

Innovations on the Horizon

Think 3D printing of custom parts, integrated sensors, and AI-assisted workflows.

Integration with Automation and AI

Smart systems + disposables = less manual labor, more consistency.

Sustainability in Single Use Assemblies

Recycling Programs

Vendors like foxxlifesciences are pioneering return-and-recycle programs to tackle waste.

Bio-Based Materials

Bioplastics and plant-based polymers are becoming part of the single use ecosystem.

Energy Efficient Manufacturing

Low-energy, low-emission production processes make a big difference over time.

Case Study: Successful Implementation

Real-World Example from foxxlifesciences

A mid-size biotech firm switched to foxxlifesciences’ custom SUAs. They saw a 40% reduction in downtime and a 25% cost saving in six months.

Results and Learnings

Quick installation, minimal training required, and glowing regulatory audits.

Tips for Implementing Single Use Assemblies

Staff Training

Your team should know how to handle and troubleshoot disposables.

Risk Assessments

Evaluate failure points and have contingency plans in place.

Pilot Testing

Start small. Test performance before full-scale integration.

Conclusion

Single Use Assemblies aren’t just a trend—they’re the future of efficient, safe, and scalable bioprocessing. Whether you're a small biotech startup or a global pharma leader, switching to SUAs can drive massive improvements in productivity, quality, and compliance. And with an industry leader like foxxlifesciences by your side, success is just a connection away.

Email Us :  sales@foxxlifesciences.com

https://www.linkedin.com/company/foxxlifesciences

[earthvitalsignimpact]

Rebuilding Ukraine’s Zero-Carbon Economy: A Strategic Vision

by UEVS and the power of AI

Andriy leaned forward, his expression serious yet filled with a quiet determination. “If we want to rebuild Ukraine as a zero-carbon economy, we must start from first principles. This is not just about replacing old infrastructure; it’s about rethinking the entire system—energy, industry, agriculture, finance, and even governance. The war may have devastated our economy, but it has also given us a unique opportunity: to build a model for the future, free from the baggage of outdated industries.”

Elana nodded. “Exactly. Many countries are struggling to transition from fossil fuels, but Ukraine, having to rebuild from the ground up, can leapfrog straight into a regenerative economy—one that restores ecosystems, prioritizes resilience, and ensures long-term sovereignty. This isn’t just about sustainability; it’s about Ukraine leading a new global paradigm.”

1. Energy Independence: From Ruins to Renewables

Andriy tapped his pen against his notebook. “The foundation of a zero-carbon economy is energy. Ukraine was heavily reliant on coal, gas, and nuclear before the war. What’s the fastest way to transition?”

Elana considered the question. “Several pathways:

Mass-scale solar & wind deployment – Ukraine has vast open lands, perfect for solar farms. Offshore wind in the Black Sea and onshore wind in the Carpathians could provide significant capacity.

Decentralized microgrids – Rather than rebuilding a centralized power grid vulnerable to attacks, invest in localized microgrids powered by renewables. AI-driven grid management can dynamically optimize power flows based on demand.

Geothermal & hydro – Tapping into Ukraine’s geothermal potential could provide baseload energy, while upgrading existing hydroelectric capacity stabilizes the grid.

Fusion & next-gen nuclear – Ukraine has a strong scientific community. Investing in solid-state battery storage, small modular reactors (SMRs), and even nuclear fusion R&D could make the country a leader in next-gen energy solutions.

“These solutions would make Ukraine energy-independent,” Elana continued. “No more reliance on imported fossil fuels. No more energy blackmail. Energy security is national security.”

Andriy exhaled sharply, nodding. “You’re right. We’ve seen how dependency can be weaponized. A decentralized, renewable grid is our best insurance policy.”

2. Industrial Decarbonization: A Revolution in Manufacturing

Andriy flipped to a new page. “What about industry? Our steel and heavy manufacturing sector were the backbone of our economy. How do we rebuild without falling back into high emissions?”

Elana smiled. “We redesign the entire supply chain:

Green hydrogen for steel & heavy industry – Instead of coal-fired steel production, use hydrogen-based direct reduction. Ukraine could produce green hydrogen using excess renewable energy.

Circular economy principles – Prioritize recycled steel, aluminum, and concrete instead of virgin materials, cutting emissions and reducing dependency on extraction.

3D printing for construction – Advanced additive manufacturing could speed up reconstruction while minimizing waste. Smart biomaterials infused with carbon-sequestering algae can even absorb CO₂ over time.

Bioplastics & sustainable materials – Ukraine can position itself as a leader in biomanufacturing, using agricultural waste to produce biodegradable plastics and eco-friendly composites.”

Andriy looked intrigued. “Green hydrogen is ambitious. Expensive, too. Can we make it cost-effective?”

Elana nodded. “With AI-driven optimization and the dropping costs of electrolyzers, Ukraine could export hydrogen to Europe, turning it into an economic advantage.”

3. Agriculture & Food Security: Regenerative Farming

Andriy sighed. “Agriculture is another challenge. Ukraine was a major food exporter, but traditional farming depletes the soil. How do we feed the population while regenerating our land?”

Elana’s eyes lit up. “By shifting to regenerative agriculture:

Agroforestry & permaculture – Integrating trees, crops, and livestock restores soil health and increases resilience to extreme weather.

Carbon farming – Incentivizing farmers to sequester CO₂ using biochar, cover cropping, and no-till farming. This could create a carbon credit economy, providing additional income.

AI-driven precision farming – Using drones, sensors, and blockchain logistics to optimize water and fertilizer use, increasing yields while reducing waste.

Protein transition – Ukraine could become a leader in lab-grown meat, insect farming

Algae-based Omega-3 production for sustainable improvement of brain performance and cardiovascular health”

Andriy chuckled. “Lab-grown borscht? I’m not sure Ukrainians are ready for that.”

Elana laughed. “Okay, maybe not that extreme. But shifting to carbon-negative farming would make Ukraine food-secure and a leader in climate-resilient agriculture.”

4. Financial Strategy: Funding the Green Revolution

Andriy leaned back. “This all sounds incredible, but let’s talk reality. How do we finance it?”

Elana’s expression turned serious. “That’s where decentralized finance (DeFi) and digital sovereignty come in:

Green Bonds & Carbon Credits – Ukraine can issue green recovery bonds to attract investment from sustainability funds.

Bitcoin & Digital Finance – Ukraine has embraced crypto. Using blockchain for funding allocation could prevent corruption and attract decentralized global capital.

Public-Private Partnerships (PPPs) – Bring in tech companies and impact investors to fund key projects.

Diaspora Investment Fund – Ukrainians abroad want to help rebuild. A global Ukrainian investment fund could attract capital without bureaucratic constraints.”

Andriy nodded, his mind racing. “So, we don’t need to wait for foreign aid. We can mobilize decentralized capital to rebuild?”

Elana smiled. “Exactly. And by using digital finance, blockchain, and decentralized governance, Ukraine ensures that its sovereignty is never compromised again.”

5. Defense & Resilience: Smart Cities & Cybersecurity

Andriy closed his notebook. “Final question: How do we ensure that our new infrastructure is resilient to future threats?”

Elana drew a sketch on a napkin. “We build AI-driven, self-sustaining smart cities:

Energy-positive buildings – Homes and offices that generate more energy than they consume through solar-integrated facades and kinetic flooring.

Hyperloop & electric transit – A modernized transport network using high-speed rail, electric buses, and bike-friendly infrastructure.

Water recycling & vertical farming – Cities with closed-loop water systems and rooftop farms for food security.

AI-driven security & cybersecurity – Using quantum cryptography to protect energy grids and AI-driven cyber defense to secure critical infrastructure.”

Andriy smiled. “You’re describing a Ukraine that doesn’t just recover—it leads the world in sustainable innovation.”

Elana placed her hand on his. “Andriy, this is possible. The question isn’t whether Ukraine can rebuild as a zero-carbon economy—the question is whether the world is ready to follow its lead.”

Andriy exhaled. “Then let’s build the future from the ashes. A stronger, cleaner, sovereign Ukraine.”

Ukraine’s New Role in the World

By rebuilding as a zero-carbon, decentralized, and digitally sovereign nation, Ukraine could: ✅ Become a global leader in clean energy and green hydrogen ✅ Export advanced sustainable manufacturing technologies ✅ Use AI and blockchain to create a fully transparent, corruption-free economy ✅ Show the world how to build a nation that is truly resilient—militarily, financially, and ecologically

🚀 Quiz: Rebuilding Ukraine as a Zero-Carbon Economy

📌 Instructions:

Multiple-choice: Choose the correct answer.

True/False: Answer whether the statement is true or false.

Short answer: Provide a brief response.

🔋 Section 1: Energy Independence

1.1 Multiple Choice

What is one of the key advantages of decentralized microgrids in Ukraine’s future energy system? A) They reduce the need for batteries B) They prevent large-scale blackouts and increase resilience C) They increase dependence on fossil fuels D) They require more imported energy

👉 Answer: B) They prevent large-scale blackouts and increase resilience

1.2 True or False

Ukraine’s zero-carbon strategy includes investing in geothermal and hydroelectric power to stabilize the energy grid.

👉 Answer: True

1.3 Short Answer

What are two cutting-edge energy technologies Ukraine could invest in for long-term clean energy solutions?

👉 Possible Answer: Nuclear fusion and small modular reactors (SMRs)

🏗️ Section 2: Industrial Decarbonization

2.1 Multiple Choice

Which green technology can replace coal in steel production? A) Carbon capture and storage B) Green hydrogen C) Biomass energy D) Fossil fuel derivatives

👉 Answer: B) Green hydrogen

2.2 True or False

3D printing in construction can reduce waste and speed up rebuilding efforts in Ukraine.

👉 Answer: True

2.3 Short Answer

Name one biodegradable material Ukraine could invest in to replace traditional plastic.

👉 Possible Answer: Bioplastics made from agricultural waste

🌾 Section 3: Agriculture, Food Security & Sustainable Nutrition

3.1 Multiple Choice

Which farming technique helps restore soil health and increase resilience? A) Monoculture farming B) Intensive pesticide use C) Agroforestry and permaculture D) Overgrazing

👉 Answer: C) Agroforestry and permaculture

3.2 True or False

AI-driven precision farming can help Ukraine reduce fertilizer and water waste.

👉 Answer: True

3.3 Short Answer

What is one innovative protein source that could reduce Ukraine’s land and water use?

👉 Possible Answer: Insect protein, lab-grown meat, or plant-based proteins like pea or lentil protein.

3.4 Multiple Choice

Which sustainable fatty acid source can be used as an alternative to fish oil for Omega-3 production? A) Palm oil B) Soybean oil C) Algae-based Omega-3 D) Canola oil

👉 Answer: C) Algae-based Omega-3

3.5 True or False

Algae-based Omega-3 is a sustainable alternative to fish oil and can help reduce overfishing.

👉 Answer: True

3.6 Short Answer

Why is algae-based Omega-3 considered a more sustainable option than traditional fish oil?

👉 Possible Answer: Algae-based Omega-3 does not contribute to overfishing, requires less water and land than fish farming, and provides a direct source of DHA and EPA without disrupting marine ecosystems.

💰 Section 4: Financial Strategy

4.1 Multiple Choice

How can blockchain and digital finance help fund Ukraine’s zero-carbon economy? A) Increase corruption and inefficiency B) Allow transparent tracking of funds and decentralized investments C) Make traditional banks obsolete overnight D) Reduce the need for foreign investments

👉 Answer: B) Allow transparent tracking of funds and decentralized investments

4.2 True or False

Ukraine’s diaspora investment fund can allow Ukrainians abroad to contribute to the country’s rebuilding efforts.

👉 Answer: True

4.3 Short Answer

What is one way Ukraine can use carbon credits to support its green economy?

👉 Possible Answer: By monetizing CO₂ sequestration through regenerative farming and reforestation projects.

🏙️ Section 5: Smart Cities & Resilience

5.1 Multiple Choice

Which technology can optimize energy use, waste management, and disaster response in a smart city? A) Fossil fuel analytics B) AI-driven urban planning C) Manual record-keeping D) Centralized, high-carbon infrastructure

👉 Answer: B) AI-driven urban planning

5.2 True or False

Hyperloop and electric transit systems are planned to replace inefficient transport networks in a zero-carbon Ukraine.

👉 Answer: True

5.3 Short Answer

What is one way AI-driven cybersecurity can protect Ukraine’s energy infrastructure?

👉 Possible Answer: AI can detect and neutralize cyberattacks on the energy grid before they cause disruption.

💡 Bonus Question

🌍 If Ukraine successfully builds a zero-carbon economy, what global impact could it have?

👉 Possible Answer: Ukraine could become a model for other nations, export green technologies, lead in hydrogen production, and increase geopolitical stability through energy independence.

🔍 Scoring Guide:

✅ 15-20 Correct Answers: Green Leader 🌱🌍 – You’re ready to help design Ukraine’s future! ✅ 10-14 Correct Answers: Sustainable Innovator ⚡🔧 – You understand the key concepts but need a bit more research. ✅ 5-9 Correct Answers: Eco-Explorer 🌿🚀 – You have potential! Time to study Ukraine’s green economy further. ✅ 0-4 Correct Answers: Climate Rookie 🌏❗ – Keep learning! Sustainability is the key to the future.

[mordormr]

Continuous Bioprocessing Market: Industry Trends, Growth, and Future Outlook

Market Overview

The Global Continuous Bioprocessing Market is projected to be valued at USD 248.77 million in 2025 and is expected to grow to USD 708.09 million by 2030, registering a CAGR of 23.27% during the forecast period (2025-2030).

Emerging Trends in the Continuous Bioprocessing Industry

1. Integration of AI and Automation

The use of artificial intelligence (AI), machine learning (ML), and process automation in continuous bioprocessing is enabling real-time monitoring, predictive maintenance, and process optimization for improved efficiency and quality control.

2. Increasing Focus on Continuous Downstream Processing

While upstream processes like continuous perfusion bioreactors are widely adopted, there is now a push to integrate continuous chromatography and filtration techniques in downstream processing for a fully continuous production workflow.

3. Development of Modular and Scalable Systems

Companies are investing in modular bioprocessing units that allow for incremental scaling and flexible manufacturing capabilities, enabling biopharma firms to adjust production volumes based on demand.

4. Advancements in Single-Use Bioreactors and Disposable Technologies

Single-use technologies are improving process flexibility and reducing contamination risks, making continuous processing more accessible and cost-effective. This is particularly beneficial for small-scale biopharma startups and CMOs.

5. Growing Adoption in Cell & Gene Therapy Manufacturing

Continuous bioprocessing is gaining traction in the cell and gene therapy sector, where highly personalized treatments require efficient, small-batch production with rapid turnaround times.

Market Challenges

1. High Initial Investment and Infrastructure Costs

Transitioning from batch to continuous bioprocessing requires significant capital investment in new equipment, process validation, and workforce training. Many small and mid-sized companies struggle with this transition due to cost constraints.

2. Regulatory Uncertainty

Continuous bioprocessing is still a relatively new approach, and regulatory bodies like the FDA and EMA are evolving guidelines to ensure safety, quality, and scalability. Companies need to navigate complex regulatory pathways before fully integrating continuous processing.

3. Process Complexity and Control Challenges

Unlike batch processes, continuous bioprocessing requires real-time process control, automation, and data analysis to maintain consistency and quality. Managing these complex workflows can be a challenge for traditional biomanufacturers.

4. Limited Adoption in Small-Scale Facilities

While large-scale pharmaceutical manufacturers are rapidly adopting continuous bioprocessing, small and mid-sized biotechs often face barriers such as high capital costs, lack of expertise, and operational complexities in implementing continuous systems.

Conclusion

The continuous bioprocessing industry is revolutionizing biopharmaceutical manufacturing by enabling faster, more efficient, and cost-effective production of biologics, biosimilars, and cell therapies. With advancements in automation, single-use technologies, and real-time process monitoring, continuous bioprocessing is becoming the preferred approach for biotech and pharmaceutical companies worldwide.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/continuous-bioprocessing-market

[rootsanalysis]

The modular facilities market is estimated to be worth USD 6.4 billion in 2030

Off-site, modular construction minimizes disruption to building timelines and logistical delays, ensuring systematic delivery of new facilities, this is particularly beneficial within the healthcare industry, where speed, sanitation and sterility are crucial

 Roots Analysis is pleased to announce the publication of its recent study, titled, “Modular Facilities in Pharmaceutical and Biotechnology Market”

 The report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 §  An in-depth review of the market landscape of players that offer services for modular facility construction for biotechnology and pharmaceutical industries, along with the details of certifications obtained and COVID-19 related initiatives undertaken by modular service providers.

§  A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size, location of headquarters, type of industry served, type of modular cleanrooms, type of modular cleanroom components. It also includes details related to regulatory approvals and certifications.

§  An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021.

§  An in-depth analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. 

§  An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players.

§  Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. 

§  An in-depth review of emerging trends, including processing technologies with modular facilities, the shift towards smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.

§  A detailed discussion on the various growth drivers and trends related to modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Modular biomanufacturing : Moreover, biopharma industry continues to seek innovative ways of optimizing drug development costs and timelines. Off-site design and modularization demonstrate great potential to provide the industry with the agility to reduce the overall time to market for a particular product.

 To Request Sample Page - https://www.rootsanalysis.com/reports/178/request-sample.html

 §  Type of Modular Construct 

§  Hybrid Skid

§  Plug-and-Play

§  Skid-Mounted

§  Truckable

§  Others

§  Type of Construction Component

§  Base Building

§  Electrical System

§  Mechanical System

§  Process Equipment

§  Process Piping

§  Process Utilities

§  Other Components

§  Purpose of Facility

§  Aseptic Filling

§  Manufacturing

§  Research and Development

§  Others

§  Facility Area

§  Very Small

§  Small

§  Mid-Sized

§  Large

§  Very Large

§  Scale of Operation

§  Clinical

§  Commercial

§  Type of Industry

§  Pharmaceutical                  

§  Biotechnology

§  Type of Product

§  Biosimilars                        

§  Cell and Gene Therapies

§  Monoclonal Antibodies

§  Vaccines

§  Other Products

§  Type of Facility

§     New Facility

§     Facility Expansions

§  Key Geographical Regions

§  North America                  

§  Europe

§  Asia

§  Middle East and North Africa

§  Latin America

§  Rest of the World

 Download Free Insights now - https://www.rootsanalysis.com/reports/178/free-insights.html

 Transcripts of interviews held with the following senior level representatives of stakeholder companies

Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)

§  François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)

§  Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)

§  Pär Almhem (President, Modwave)

§  Sulogna Roy (Ex Sales Manager, Zeton)

§  Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

 Key companies covered in the report

§  Cytiva

§  G-CON Manufacturing

§  Pharmadule Morimatsu

§  NNE

§  IPM Technologies

§  KeyPlants

§  Germfree Laboratories

§  ModuleCO Pharma

 For more information, please click on the following link

https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html

 You may also be interested in the following titles:

1.      Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030

2.      Biopharmaceutical CROs Market, 2021-2030

3.      Continuous Manufacturing Equipment Providers Market, 2021-2030

4.      DNA-Encoded Libraries: Platforms and Services Market

5.      Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[sanemyamen]

Flexible Biomanufacturing Platform Market to Witness Excellent Revenue Growth Owing to Rapid Increase in Demand

Global Flexible Biomanufacturing Platform Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, players market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. Major Players in This Report Include GE Healthcare Life Sciences (United States),Patheon, Inc. (United States),JHL Biotech (China),Xcellerex, Inc. (United States),McKinsey & Company (United States),Nelson Biomedical (Nigeria),Setpoint Systems, Inc. (United States),R-Pharm (Russia),Blue Ocean Biomanufacturing (United States)

The flexible biomanufacturing platform is defined by operational and functional integration in the biomanufacturing process in order to react swiftly to changing markets and production capacity demands for quality, cost, complexity, and scale improvements. Various flexible models for biomanufacturing plants have been presented, which can be adjusted according to program needs. The flexible biomanufacturing platform incorporates a number of tools in the process, including the ability to manufacture multiple products with the quick changeover, simple manufacturing process adoption, support for both large and small volume production requirements, and easy conversion from clinical to commercial production. Equipment, processes, and manufacturing can all be made more flexible.

Market Drivers New Product Development toward more Personalized Products

Increasing Pressure to Reduce Manufacturing Costs

Market Trend Advancements in Bioprocesses and Capabilities

Rapid Increase in Product Approvals in the Pharmaceutical Sector

Opportunities Globalization of the Biopharmaceutical Industry

Rising Number of Complex Molecules in the Biologic Pipeline

Challenges Regulatory Requirements

Requirement of Substantial Pre-planning

The Flexible Biomanufacturing Platform market study is being classified by Type (Single-use Technology, Modular Environment, Advanced Process Automation, Standardization), Modality (Machine Flexibility, Material Handling Flexibility, Operational Flexibility) Presented By

AMA Research & Media LLP

[emma-what-son]

Plastic: Next to the burning of fossil fuels, it represents one of the greatest environmental threats facing the planet. Researchers estimate that since 1950, more than 8.3 billion metric tons of the stuff has been produced, more than one ton for every person currently on the planet. Once used, much of it is burned. The rest winds up in landfills or in the ocean, where it can take up to five centuries to fully decompose. In the meantime, it poses a threat to wildlife and, through potentially carcinogenic microplastics that enter the food chain, us too. London-based startup FabricNano is targeting this scourge with a new kind of manufacturing that harnesses the chemical laboratories that exist inside the cells of living organisms, but does so without the need to actually use living things. Its first product is a precursor for the creation of biodegradable polyester, which FabricNano’s founders think they can produce at a price that will make it competitive with the petroleum-based plastics that are used in everything from water bottles to fast-food trays. Among those inspired by that vision are actress Emma Watson of Harry Potter fame, Twitter co-founder Biz Stone, and Alexander Moscho, the former chief executive of Bayer. They are part of a $12.5 million investment round in FabricNano, led by London-based venture capital firm Atomico, announced today.

Harvesting the power of single-cell organisms is one of humankind’s oldest manufacturing techniques: Think of beer, wine, cheese and bread. Traditional biomanufacturing uses microbes, such as yeast, that either naturally produce a chemical or, more recently, that have been genetically modified to do so. But there are several potential problems: Growing single-cell organisms in large vats can be difficult. The amount of chemical produced, known as the yield, can be inconsistent, especially because the cells at the bottom of the vats often respond poorly to the pressure and heat created. Evenly distributing food for the cells can be a problem. For many chemical processes, cells are also relatively inefficient, partly because the cells need to consume energy to live. This tends to make biomanufacturing expensive compared to other chemical processes, so it is most often used for specialty chemicals and materials. Think pharmaceuticals, cosmetics, carpeting, and molded parts in automobiles. Biomanufacturing also doesn't work for certain chemicals because the chain reactions needed to create them produce toxins that kill the cells before the process can be completed. FabricNano is one of just a handful of companies working to commercialize a technology that sidesteps many of these pitfalls, known as “cell-free biomanufacturing.” Other companies also working in the area include San Diego startup Debut Biotech, which has a partnership with Dutch materials company DSM; Daicel Arbor Biosciences in Ann Arbor, Mich., which is mostly focused on uses of the technology in life science;, and French biotech company Synthelis.

In FabricNano’s case, it has pioneered a wafer-like substance made of DNA suspended in liquid that forms a kind of platform on which various enzymes and proteins can produce the same chemical reactions as would occur inside a cell, but without the need for an actual living organism. Because there are no living cells, the chemical reactions are more efficient, can be used in large vats without worrying about inconsistent yields, and can produce chemicals that would prove toxic to cells. "Cell-free is the technology that I'd wish we'd had ten years ago when I was trying to source biodegradable materials for Unilever," says Mike Butler, who served as a research and development director at the consumer products giant specifically working on sustainability and advanced materials from 2008 to 2018. At the time, Butler says, only cell-based biomanufacturing processes were available. But they were "too tricky to optimize," because of the difficulty of "keeping all the little bugs happy," he says, referring to the microbes. While Butler says "there is some really great stuff out there" in terms of biodegradable plastics, they tend to be between three and five times more expensive than conventional petroleum-based plastics. As a result, Unilever and other companies have largely built their sustainability strategies around the use of recycled plastic rather than biodegradable or compostable materials. New technologies could alter that equation, he says. (Now the technical director at U.K. specialty chemicals company William Blythe Ltd., Butler has consulted with FabricNano on how to commercialize its technology.) FabricNano's DNA-based wafer is critical, says John Woodley, a chemical engineering professor at the Technical University of Denmark who serves as a scientific advisor to FabricNano. “It holds the enzymes together and positions them the right way, so they are very close to each other,” he says. This makes the chemical reactions controllable and efficient. Siraj Khaliq, a partner at Atomico who led the financing round and will be joining FabricNano’s board, says the venture capital firm found the modular nature of FabricNano’s DNA wafer technology was compelling. “There are all kinds of benefits that come from controlling and being able to build with biology as you would with hardware,” he tells Fortune. FabricNano’s system makes it cheaper to manufacture some chemicals, such as one called 1,3 propanediol. Currently, 1,3 propanediol can be biomanufactured and turned into biodegradable plastic, but not at a price that is competitive with the petroleum-based single-use plastics. “Why is Coke not shifting to bio-based plastics? Because it’s too expensive and the market is too price sensitive,” says Grant Aarons, FabricNano’s co-founder and chief executive. For instance, DuPont produces a biodegradable nylon, called Biomax PTT, that is made from biomanufactured 1,3 propanediol. But it costs about $3 per kilogram, whereas petroleum-based plastics cost just $1 per kilogram, Aarons says. (Fortune wrote about a similar biomanufactured product from Cargill Dow in 2003.) Woodley says that FabricNano’s cell-free process could close this gap. “1,3 propanediol is a well-established chemical product, but it is expensive and, basically, it is too slow to biomanufacture,” he says. “There is an opportunity to drive this much faster and bring the price down.” FabricNano can convert sugars that are used as feed stock for the chemical reaction to the plastic end product with nearly 100% efficiency, compared to about 40% efficiency inside living cells, Aarons says. What’s more, because the company isn't using living cells, the sugars it uses don’t have to be particularly pure. FabricNano can use waste glycerin that is a byproduct of biodiesel production, and is often simply burned by biodiesel producers because there’s currently no market for it, to power its process. Although Aarons says three large chemical companies that he declined to name have shown interest in FabricNano's

product, the company has not started shipping any of it. He said the company would use the money from the current funding round to ensure that it could scale up its production of the DNA wafers and perfect its process for creating 1,3 propanediol. The same cell-free method can also be used to produce other chemicals and materials, including pharmaceuticals, the CEO says. Woodley says the biggest limitation to FabricNano’s success may be finding a reliable and inexpensive source of the enzymes used in the chemical reaction. In living organisms, most of the enzymes are produced by the cells themselves, or the organism ingests them from the environment. In FabricNano’s case, the enzymes must be purchased. Watson, who played Hermione in the Harry Potter franchise, became a seed investor in FabricNano after being approached by the company on the advice of Atomico and Tania Boler, the founder of Elvie, a startup that makes innovative technology for women, including a breast pump. Boler is also a seed investor in FabricNano. She formerly had roles in several development organizations and at the United Nations cultural organization UNESCO. Watson is currently the United Nations Women Goodwill Ambassador and interested in environmental causes. Other venture capital firms taking part in the financing round include Backed, Hoxton Ventures, and Entrepreneur First. The latest funding brings the total amount of venture capital FabricNano has raised to $16 million.

[un-enfant-immature]

As biological manufacturing moves to the mainstream, Synvitrobio rebrands and raises cash

The pace at which the scientific breakthroughs working to bend the machinery of life to the whims of manufacturing have transformed into real businesses has intensified competition in the biomanufacturing market.

That’s just one reason why Synvitrobio is rebranding as it takes on $2.6 million in new financing to pursue opportunities in biopharmaceutical and biochemical manufacturing. Under its new name, Tierra Biosciences, the company hopes to emphasize its focus on agricultural and biochemical products.

The company is one of several looking to commercialize the field of “cell-free” manufacturing — where biological engineers strip down the cellular building blocks of life to their most basic components to create processes that ideally can be more easily manipulated to produce different kinds of chemicals.

There’s a standard way to create these cell free processes (described quite nicely in The Economist).

Grab a few quarts of culture with some kind of bacteria, plant or animal cells in it. Then use pressure to force the cells through a valve to break up their membranes and DNA . Give the goo a nice warm environment heated to roughly the average temperature of a human body for about an hour. That activates enzymes that will eat the existing DNA.

Put all of it in a centrifuge to separate out the ribosomes (which are the important bits). Take those ribosomes and give them a mixture of sugars, amino acids, adenosine triphosphate (the molecular compound that breaks down to provide energy for all biological functions), and new DNA with a different set of instructions on what to make and voila! Micro-factories in a test tube.

Along with co-founders Richard Murray, of the California Institute of Technology, and George Church, one of the living legends of modern genetics, chief executive officer Zachary Sun designed Tierra to be an engine for new biochemical discovery.

“Everything floats in the cytoplasm… We keep that internal stuff and that allows us to run reactions where a cell wall isn’t necessary. I want to reduce the complex system down to its component parts,” says Sun. “We look at this as a data collection problem. We want to use cell free to tell you what to put either in a cell or in cell free systems… We can collect more data faster using our cell free system.”

The startup is already working with the Department of Energy research institution at Oak Ridge National Laboratory to develop processes to create vanillin (vanilla extract) and mevalonate (turpentine) from biomass.

It’s an approach that is already showing the potential for investment returns in life sciences and pharmaceuticals. For inspiration, Tierra can look to the South San Francisco-based Sutro Biopharma.

That company has signed a drug discovery agreement with Merck to develop new immune-modulating therapies (that bring the immune system into check) for cancer and auto-immune disorders, in a deal worth up to $1.6 billion if the company hits certain milestones — in addition to a $60 million upfront payment. Sutro raised over $85 million in new funding in July (from investors including Merck) and just filed to go public on the Nasdaq.

According to Sun, the newly-named Tierra has its own partnerships with global 2000 companies in the works. “We’re looking to scale those commitments. We see the application space as being this natural products environment,” he says.

There’re multiple avenues to pursue with the technology widely applicable to everything from pesticides to pharmaceuticals, flavorings, and even energy.

Cyclotron Road team photos. 2016. Zachary Sun

“Synthetic biology at its core is about applying engineering best practices to speed up the ‘design-build-test’ cycles in the reprogramming of existing or construction of new biological systems. By component-izing and modularizing the cell they can radically increase the speed of those cycles,” says Seth Bannon, a co-founder of the venture capital firm Fifty Years, which invests in startups commercializing “frontier” science. 

For the investors, entrepreneurs and reporters who witnessed the birth of the cleantech bubble a decade ago and then tracked its implosion in subsequent years, the excitement this kind of technology elicits is another of history’s rhymes.

Technologies like Tierra’s aren’t new. San Diego-based Genomatica has been working on biological manufacturing for the past 18 years. The company is now exploring a cell-free system to grow chemicals that are used in the manufacture of materials like Lycra. Since 2008, Medford, Mass.-based GreenLight Biosciences has been working to bring its own biologically-based zero-calorie sugar substitute to market.

What may be different now is the maturity of the technologies that are being commercialized and the perspective of the startups coming to market — who have the benefit of avoiding the missteps made by an earlier generation.

Investors led by Social Capital with participation from Fifty Years, KdT Ventures and angel investors seem to see a difference in these companies. And large research institutions are also marshaling resources to support the vision laid out by Sun, Murray and Church. DARPA, the National Institutes of Health, the Department of Energy, Cyclotron Road and Lawrence Berkeley National Laboratory, the National Science Foundation, and the Gates Foundation have all backed the company as well.

“So many therapeutic molecules come from nature. As the DNA of plants, animals, and microbes is read in exponentially increasing volume, we expect to find useful and game-changing chemistry encoded by it. Tierra’s platform will allow us to look for molecules which might otherwise be buried in the complexity of cells’ metabolism,” says Louis Metzger, Chief Scientific Officer of Tierra, who comes from a background of drug discovery.

[cleaningpoint-blog]

The Cell Therapy Manufacturing Market is projected to grow at an annualized rate of >16.5%, till 2030

Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030, covering various important aspects of the industry and identifying key future growth opportunities.

Key Market Insights

·        More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis

·        The market is fragmented, featuring both established players and new entrants, which claim to operate at various scales and manufacture a diverse range of cell therapies

·        In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; presently, the US, the UK and China are the key hubs for cell therapy manufacturing

·        In recent years, a significant increase in partnership activity has been observed in this domain; in fact, therapy developers have already inked manufacturing deals with both indigenous and international experts

·        In order to enhance core competencies related to the domain, both drug developers and CMOs are actively investing in expanding their existing infrastructure and capabilities

·        Cell therapy manufacturers are also gradually opting to automate various operations in the supply chain; the primary objective is to achieve favorable bench-to-clinic timelines and cut down on production related losses

·        Currently, the installed global capacity for cell therapy manufacturing is estimated to be spread across 1.2+ million square feet of dedicated cleanroom area distributed across various scales of operation

·        More than 70,000 patients were estimated to have been enrolled in cell therapy related clinical trials; the demand for cell therapies is anticipated to grow significantly over the next decade

·        Revenues from manufacturing operations of T-cell therapies are anticipated to capture higher market share; the benefit will be realized by both autologous and allogeneic therapies across different regions the world

·        Clinical scale manufacturing operations are likely to drive the future market size, taking into consideration both in-house and contract service requirements

Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html    

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Table of Contents

1.   PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2.   EXECUTIVE SUMMARY

3.   INTRODUCTION

3.1. Context and Background

3.2. Introduction to Cell Therapies

3.2.1.   Comparison of Cell Therapies and Other Biotechnology Products

3.2.2.   Classification of Advanced Therapy Medicinal Products (ATMPs)

3.2.3.   Current Market Landscape of ATMPs

3.3. Overview of Cell Therapy Manufacturing

3.4. Cell Therapy Manufacturing Models

3.4.1.   Centralized Manufacturing

3.4.2.   Decentralized Manufacturing

3.5. Scalability of Cell Therapy Manufacturing

3.5.1.   Scale-up

3.5.2.   Scale-out

3.6. Types of Cell Therapy Manufacturers

3.7. Key Manufacturing-related Challenges

3.8. Factors Influencing Cell Therapy Manufacturing

3.9. Automating Cell Therapy Manufacturing

3.10.            Cell Therapy Manufacturing Supply Chain

3.11.            Future Perspectives

4.   MARKET OVERVIEW

4.1. Chapter Overview

4.2. Cell Therapy Manufacturers (Industry Players): Overall Market Landscape

4.2.1.   Analysis by Location of Headquarters

4.2.2.   Analysis by Location of Manufacturing Facility

4.2.3.   Analysis by Type of Cells Manufactured

4.2.4.   Analysis by Source of Cells

4.2.5.   Analysis by Scale of Operation

4.2.6.   Analysis by Type of Cell Culture

4.2.7.   Analysis by Purpose of Production

4.2.8.   Analysis by Manufacturing Capabilities / Services

4.3. Cell Therapy Manufacturers (Non-Industry Players): Overall Market Landscape

4.3.1.   Analysis by Location of Headquarters

4.3.2.   Analysis by Location of Manufacturing Facility

4.3.3.   Analysis by Type of Cells Manufactured

4.3.4.   Analysis by Source of Cells

4.3.5.   Analysis by Scale of Operation

4.3.6.   Analysis by Type of Cell Culture

4.3.7.   Analysis by Purpose of Production

4.3.8.   Analysis by Manufacturing Capabilities / Services

4.4. Cell Therapy Manufacturing: Role of Logistics Service Providers

5.   REGULATORY LANDSCAPE

5.1. Chapter Overview

5.2. Current Scenario

5.2.1.   Regulatory Guidelines in the US

5.2.2.   Regulatory Guidelines in Europe

5.2.3.   Regulatory Guidelines in Japan

5.2.4.   Conditional Approvals

5.3. Regulatory Accreditations for Cell Therapy Manufacturing

5.3.1.   Facilities Approved by Regulators to Manufacture Cell Therapies

5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies

5.5. Existing Challenges to Clinical-Stage Manufacturing

5.5.1.   Variability in Regulatory Guidelines across Different Geographies

5.6. Conclusion

6.   ROADMAPS FOR OVERCOMING EXISTING CHALLENGES

6.1. Chapter Overview

6.2. Roadmap for the US

6.2.1.   Cell Processing

6.2.2.   Cell Preservation, Distribution and Handling

6.2.3.   Process Automation and Data Analytics

6.2.4.   Process Monitoring and Quality Control

6.2.5.   Standardization and Regulatory Support

6.2.6.   Workforce Development

6.2.7.   Supply Chain and Logistics

6.3. Roadmaps for Other Geographies

6.3.1.   Europe

6.3.2.   Asia Pacific

7.   AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

7.1. Chapter Overview

7.2. Automation of Cell Therapy Manufacturing Processes

7.2.1.   Closed Systems

7.2.2.   Single-use Systems

7.2.3.   Modular Systems

7.3. Case Studies

7.3.1.   Roadmap to Developing an Automated Cell Manufacturing / Processing Device

7.3.2.   Automating Cell Therapy Manufacturing

7.4. GMP-in-a-Box

7.5. List of Automation Service Providers

7.6. Comparative Analysis of Manual and Automated Processes

7.7. Concluding Remarks

8.   PROFILES: INDUSTRY PLAYERS

8.1. Chapter Overview

8.2. Service Providers in the US

8.2.1        Cognate BioServices

8.2.1.1.      Company Overview

8.2.1.2.      Service Portfolio

8.2.1.3.      Manufacturing Capabilities

8.2.1.4.      Partnerships

8.2.1.5.      Future Outlook

8.2.2.   FUJIFILM Cellular Dynamics

8.2.2.1.      Company Overview

8.2.2.2.      Service Portfolio

8.2.2.3.      Manufacturing Capabilities

8.2.2.4.      Partnerships

8.2.2.5.      Future Outlook

8.2.3.   KBI Biopharma

8.2.3.1.      Company Overview

8.2.3.2.      Service Portfolio

8.2.3.3.      Manufacturing Capabilities

8.2.3.4.      Partnerships

8.2.3.5.      Future Outlook

8.2.4.   Hitachi Chemical Advanced Therapeutics Solutions

8.2.4.1.      Company Overview

8.2.4.2.      Service Portfolio

8.2.4.3.      Manufacturing Capabilities

8.2.4.4.      Partnerships

8.2.4.5.      Future Outlook

8.2.5.   Waisman Biomanufacturing

8.2.5.1.      Company Overview

8.2.5.2.      Service Portfolio

8.2.5.3.      Manufacturing Capabilities

8.2.5.4.      Partnerships

8.2.5.5.      Future Outlook

8.3. Service Providers in Europe

8.3.1.   BioNTech Innovative Manufacturing Services

8.3.1.1.      Company Overview

8.3.1.2.      Service Portfolio

8.3.1.3.      Manufacturing Capabilities

8.3.1.4.      Partnerships

8.3.1.5.      Future Outlook

8.3.2.   Cell and Gene Therapy Catapult

8.3.2.1.      Company Overview

8.3.2.2.      Service Portfolio

8.3.2.3.      Manufacturing Capabilities

8.3.2.4.      Partnerships

8.3.2.5.      Future Outlook

8.3.3.   Lonza

8.3.3.1.      Company Overview

8.3.3.2.      Service Portfolio

8.3.3.3.      Manufacturing Capabilities

8.3.3.4.      Partnerships

8.3.3.5.      Future Outlook

8.3.4.   MaSTherCell

8.3.4.1.      Company Overview

8.3.4.2.      Service Portfolio

8.3.4.3.      Manufacturing Capabilities

8.3.4.4.      Partnerships

8.3.4.5.      Future Outlook

8.3.5.   Roslin Cell Therapies

8.3.5.1.      Company Overview

8.3.5.2.      Service Portfolio

8.3.5.3.      Manufacturing Capabilities

8.3.5.4.      Partnerships

8.3.5.5.      Future Outlook

8.4. Service Providers in Asia Pacific

8.4.1.   Cell Therapies

8.4.1.1.      Company Overview

8.4.1.2.      Service Portfolio

8.4.1.3.      Manufacturing Capabilities

8.4.1.4.      Partnerships

8.4.1.5.      Future Outlook

8.4.2.   Japan Tissue Engineering (J-TEC)

8.4.2.1.      Company Overview

8.4.2.2.      Service Portfolio

8.4.2.3.      Manufacturing Capabilities

8.4.2.4.      Partnerships

8.4.2.5.      Future Outlook

8.4.3.   MEDINET

8.4.3.1.      Company Overview

8.4.3.2.      Service Portfolio

8.4.3.3.      Manufacturing Capabilities

8.4.3.4.      Partnerships

8.4.3.5.      Future Outlook

8.4.4.   Nikon CeLL innovation

8.4.4.1.      Company Overview

8.4.4.2.      Service Portfolio

8.4.4.3.      Manufacturing Capabilities

8.4.4.4.      Partnerships

8.4.4.5.      Future Outlook

8.4.5.   WuXi Advanced Therapies

8.4.5.1.      Company Overview

8.4.5.2.      Service Portfolio

8.4.5.3.      Manufacturing Capabilities

8.4.5.4.      Partnerships

8.4.5.5.      Future Outlook

9.   PROFILES: NON-INDUSTRY PLAYERS

9.1. Chapter Overview

9.2. Center for Cell and Gene Therapy, Baylor College of Medicine

9.2.1.   Overview

9.2.2.   Operating Segments

9.2.3.   Service Portfolio

9.2.4.   Manufacturing Facilities and Capabilities

9.3. Centre for Cell Manufacturing Ireland, National University of Ireland

9.3.1.   Overview

9.3.2.   Service Portfolio

9.3.3.   Manufacturing Facilities and Capabilities

9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania

9.4.1.   Overview

9.4.2.   Service Portfolio

9.4.3.   Manufacturing Facilities and Capabilities

9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital

9.5.1.   Overview

9.5.2.   Service Portfolio

9.5.3.   Manufacturing Facilities and Capabilities

9.6. Laboratory for Cell and Gene Medicine, Stanford University

9.6.1.   Overview

9.6.2.   Service Portfolio

9.6.3.   Manufacturing Facilities and Capabilities

9.7. Molecular and Cellular Therapeutics, University of Minnesota

9.7.1.   Overview

9.7.2.   Service Portfolio

9.7.3.   Manufacturing Facilities and Capabilities

9.8. Newcastle Cellular Therapies Facility, Newcastle University

9.8.1.   Overview

9.8.2.   Service Portfolio

9.8.3.   Manufacturing Facilities and Capabilities

9.9. Rayne Cell Therapy Suite, King’s College London

9.9.1.   Overview

9.9.2.   Manufacturing Facilities and Capabilities

9.10.            Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine

9.10.1.               Overview

9.10.2.               Manufacturing Facilities and Capabilities

9.11.            Sydney Cell and Gene Therapy

9.11.1.               Overview

9.11.2.               Manufacturing Facilities and Capabilities

10.ROLE OF NON-PROFIT ORGANIZATIONS

10.1.            Chapter Overview

10.2.            Cell Therapy Manufacturing Service Providers: Non-Profit Organizations

10.2.1.               CellCAN

10.2.2.               Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)

10.2.3.               National Cell Manufacturing Consortium (NCMC)

10.2.4.               California Institute of Regenerative Medicine (CIRM)

10.3.            Cell Therapy Manufacturing: Affiliated International Societies

11.PARTNERSHIPS

11.1.            Chapter Overview

11.2.            Partnership Models

11.3.            Cell Therapy Manufacturing: List of Partnerships

11.3.1.               Analysis by Year of Partnership

11.3.2.               Analysis by Type of Partnership Model

11.3.3.               Analysis by Year and Type of Partnership Model

11.4.            Analysis by Type of Cells

11.5.            Analysis by Scale of Operation

11.6.            Geographical Analysis

11.6.1.               Continent-wise Distribution

11.6.2.               Country-wise Distribution

11.7.            Most Active Players: Analysis by Number of Partnerships

11.8.            Cell Therapy Manufacturing: List of Acquisitions

11.8.1.               Analysis by Year and Type of Cells

11.8.2.               Geographical Analysis

11.8.3.               Ownership Change Matrix

12.FACILITY EXPANSIONS

12.1.            Chapter Overview

12.2.            Cell Therapy Manufacturing: List of Expansions

12.2.1.               Cumulative Year-wise Distribution

12.2.2.               Analysis by Type of Cells

12.2.3.               Analysis by Scale of Operation

12.2.4.               Analysis by Purpose of Expansion  

12.2.5.               Analysis by Location of Manufacturing Facility

12.2.6.               Analysis by Region and Purpose of Expansion

13.CAPACITY ANALYSIS

13.1.            Chapter Overview

13.2.            Key Assumptions and Methodology (Industry Players)

13.2.1      Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)

13.2.1.1.    Analysis by Size of Manufacturer

13.2.1.2.    Analysis by Scale of Operation

13.2.1.3.    Analysis by Location of Manufacturing Facility

13.2.2.               Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)

13.2.2.1.    Analysis by Size of Manufacturer

13.2.2.2.    Analysis by Scale of Operation

13.2.2.3.    Analysis by Location of Manufacturing Facility

 13.3.            Key Assumptions and Methodology (Non-Industry Players)

13.3.1.               Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)

13.3.1.1.    Analysis by Scale of Operation

13.3.1.2.    Analysis by Location of Manufacturing Facility

13.3.2.               Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)

13.3.2.1.    Analysis by Scale of Operation

13.3.2.2.    Analysis by Location of Manufacturing Facility

13.4         Concluding Remarks

14.DEMAND ANALYSIS

14.1         Chapter Overview

14.2         Key Assumptions and Methodology

14.3         Cell Therapy Manufacturing: Overall Annual Demand

14.3.1.     Analysis by Type of Cells

14.3.2.     Analysis by Scale of Operations

14.3.3.     Analysis by Geography

15.COST PRICE ANALYSIS

15.1.            Chapter Overview

15.2.            Factors Contributing to the High Price of Cell Therapies

15.3.            Pricing Models for Cell Therapies

15.3.1.               Based on Associated Costs for T-cell Therapies

15.3.2.               Based on Associated Costs for Stem Cell Therapies

15.3.3.               Based on Availability of Competing Products

15.3.4.               Based on Target Patient Segment

15.3.5.               Based on Opinions of Industry Experts

15.4.            Cell Therapy Cost Optimization

15.4.1.               Role of Cost of Goods Sold

15.4.2.               Role of Automation

15.4.3.               Role of Cell Therapy Contract Manufacturing Organizations

15.5.            Reimbursement-related Considerations for Cell Therapies

15.5.1.               Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

16.MAKE VERSUS BUY DECISION MAKING FRAMEWORK

16.1.            Chapter Overview

16.2.            Make versus Buy Decision Making: Analytical Output

17.MARKET SIZING AND OPPORTUNITY ANALYSIS

17.1.            Chapter Overview

17.2.            Scope of the Forecast

17.3.            Forecast Methodology

17.4.            Input Tables and Key Assumptions

17.5.            Overall Cell Therapy Manufacturing Market, 2019-2030

17.5.1.               Cell Therapy Manufacturing Market, 2019-2030: Distribution by Type of Cell Therapy

17.5.2.               Cell Therapy Manufacturing Market, 2019-2030: Distribution by Source of Cells

17.5.3.               Cell Therapy Manufacturing Market, 2019-2030: Distribution by Scale of Operation

17.5.4.               Cell Therapy Manufacturing Market, 2019-2030: Distribution by Purpose of

17.5.5.               Production    

17.5.6.               Cell Therapy Manufacturing Market, 2019-2030: Geographical Distribution

17.6.            Market Opportunity in Commercial Scale Manufacturing of Cell-based Therapies

17.6.1.               Overall Commercial Scale Manufacturing Market for T-cell Therapies, 2019-2030

17.6.1.1.    Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, and TIL Therapy)

17.6.1.2.    Distribution by Source of Cells

17.6.1.3.    Geographical Distribution

17.6.2.               Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030

17.6.2.1.    Distribution by Type of Therapy (Dendritic Cell Therapy, and Tumor Cell Therapy)

17.6.2.2.    Distribution by Source of Cells

17.6.2.3.    Geographical Distribution

17.6.3.               Overall Commercial Scale Manufacturing Market for NK Cell Therapies, 2019-2030

17.6.3.1.    Distribution by Source of Cells

17.6.3.2.    Geographical Distribution

17.6.4.               Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, 2019-2030

17.6.4.1.    Distribution by Source of Cells

17.6.4.2.    Geographical Distribution

17.7.            Market Opportunity in Clinical Scale Manufacturing of Cell-based Therapies

17.7.1.               Overall Clinical Scale Manufacturing Market for T-cell Therapies, 2019-2030

17.7.1.1.    Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy and TIL Therapy)

17.7.1.2.    Distribution by Source of Cells

17.7.1.3.    Geographical Distribution

17.7.2.               Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030

17.7.2.1.    Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)

17.7.2.2.    Distribution by Source of Cells

17.7.2.3.    Geographical Distribution

17.7.3.               Overall Clinical Scale Manufacturing Market for NK Cell Therapies, 2019-2030

17.7.3.1.    Distribution by Source of Cells

17.7.3.2.    Geographical Distribution

17.7.4.               Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, 2019-2030

17.7.4.1.    Distribution by Source of Cells

17.7.4.2.    Geographical Distribution

18.KEY INSIGHTS

18.1.            Chapter Overview

18.2.            Cell Therapy Manufacturers: Grid Analysis

18.3.            Cell Therapy Manufacturers: Logo Landscape by Type of Cell Therapy

18.3.1.               Logo Landscape: Immune Cell Manufacturers

18.3.2.               Logo Landscape: Stem Cell Manufacturers

18.4.            Cell Therapy Manufacturers: World Map Representation of Location of Manufacturing Facility

18.4.1.               Industry Players

18.4.2.               Non-Industry Players

19.SWOT ANALYSIS

19.1.            Chapter Overview

19.2.            Strengths

19.3.            Weaknesses

19.4.            Opportunities

19.5.            Threats

19.6.            Comparison of SWOT Factors

19.6.1.               Concluding Remarks

20.CONCLUSION

20.1.            Chapter Overview

20.2.            Key Takeaways

21.SURVEY ANALYSIS

21.1.            Chapter Overview

21.2.            Seniority Level of Respondents

21.3.            Type of Cell Therapy

21.4.            Scale of Operation

21.5.            Source of Cells

21.6.            Type of Cell Culture System

22.7.        Availability of Fill / Finish Services

22.INTERVIEW TRANSCRIPTS

22.1.            Chapter Overview

22.2.            Lion TCR

22.2.1.               Company Overview

22.2.2.               Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer

22.3.            Cell Therapies

22.3.1.               Company Overview

22.3.2.               Interview Transcript: Tim Oldham, Chief Executive Officer  

22.4.            CiMaas

22.4.1.               Company Overview

22.4.2.               Interview Transcript: Gerard MJ Bos, Chief Executive Officer

22.5.            Gracell Biotechnologies

22.5.1.               Company Overview

22.5.2.               Interview Transcript:  Wei (William) Cao, Chief Executive Officer

22.6.            Glycostem Therapeutics

22.6.1.               Company Overview

22.6.2.               Interview Transcript: Troels Jordansen, Chief Executive Officer

22.7.            Kadimastem

22.7.1.               Company Overview

22.7.2.               Interview Transcript: Arik Hasson, Executive VP Research and Development

22.8.            Bio Elpida

22.8.1.               Company Overview

22.8.2.               Interview Transcript: Gilles Devillers, General Manager

22.9.            Center for Commercialization of Cancer Immunotherapy / C3i

22.9.1.               Company Overview

22.9.2.               Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit

22.10.         Waisman Biomanufacturing

22.10.1.             Company Overview

22.10.2.             Interview Transcript: Brian Dattilo, Manager of Business Development

22.11.         RoslinCT

22.11.1.             Company Overview

22.11.2.             Interview Transcript: Fiona Bellot, Business Development Manager

22.12.         Yposkesi

22.12.1.             Company Overview

22.12.2.             Interview Transcript: Mathilde Girard, Leader, Cell Therapy Innovation and Development

22.13.         University of Minnesota

22.13.1.             Organization Overview

22.13.2.             Interview Transcript: David Mckenna, Professor and American Red in Transfusion Medicine

23.APPENDIX 1: TABULATED DATA

24.APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

[sfoxxlife]

Single use Technologies

In the rapidly advancing world of biopharmaceutical manufacturing, Single Use Technologies (SUTs) have emerged as a game-changer. These innovative solutions offer increased efficiency, cost savings, and reduced contamination risks, making them the preferred choice for modern bioprocessing. Foxx Life Sciences is a leading provider of high-quality single-use bioprocess solutions, designed to meet the stringent requirements of the biotech and pharmaceutical industries.

Email Us : sales@foxxlifesciences.com

What Are Single Use Technologies?

Single Use Technologies refer to disposable components and systems used in bioprocessing. These include bioreactors, filtration systems, sampling devices, mixing systems, and storage containers made from specialized, high-grade plastic materials. Unlike traditional stainless-steel systems, single-use components eliminate the need for cleaning and sterilization, reducing downtime and operational costs.

Benefits of Single Use Technologies

Enhanced Efficiency – Single-use systems significantly reduce setup and turnaround times, allowing for faster production cycles.

Reduced Contamination Risk – Since single-use components are pre-sterilized and disposed of after use, the chances of cross-contamination are minimized.

Lower Costs – Eliminating cleaning and sterilization processes reduces labor, water, and energy expenses.

Greater Flexibility – These systems support modular and scalable production, making them ideal for various batch sizes and applications.

Environmental Impact – While disposal is a concern, advancements in recyclable and biodegradable materials are addressing sustainability challenges.

Why Choose Foxx Life Sciences for Single Use Bioprocess Solutions?

Foxx Life Sciences offers a comprehensive range of single-use bioprocess solutions tailored to meet the growing demands of the industry. The company is known for its commitment to quality, innovation, and regulatory compliance, ensuring optimal performance in critical bioprocessing applications.

Featured Single Use Technologies at Foxx Life Sciences:

Single Use Bioprocess Bags – Designed for storage, mixing, and transportation of biopharmaceutical fluids.

Sterile Fluid Transfer Assemblies – Pre-assembled systems for secure fluid handling.

Single Use Tubing & Connectors – High-quality components to support sterile and efficient bioprocessing workflows.

Customized Solutions – Tailored single-use assemblies to fit specific process requirements.

Explore Foxx Life Sciences' Single Use Bioprocess Solutions

To discover a wide range of high-quality Single Use Technologies, visit Foxx Life Sciences. Whether you are looking for bioreactor bags, sterile sampling solutions, or innovative fluid transfer systems, Foxx Life Sciences has the expertise and products to enhance your bioprocessing operations.

Conclusion

The adoption of Single Use Technologies is transforming the biopharmaceutical industry by enhancing efficiency, reducing costs, and ensuring sterility. Foxx Life Sciences remains at the forefront of this evolution, offering cutting-edge single-use bioprocess solutions to meet the growing demands of modern biomanufacturing. Explore their offerings today and take your bioprocessing to the next level!

Contact Us : sales@foxxlifesciences.com

https://www.linkedin.com/company/foxxlifesciences

Single use Technologies

[mordormr]

The Single-use Bioprocessing Market: Driving Innovation in Biopharmaceutical Manufacturing

The Single-use Bioprocessing Market is projected to grow from USD 1.58 billion in 2025 to USD 3.36 billion by 2030, registering a robust compound annual growth rate (CAGR) of 16.26% during the forecast period (2025-2030).

The biopharmaceutical industry has witnessed remarkable growth over the past decade, fueled by advancements in biotechnology, increased demand for personalized medicine, and the global focus on vaccine development. A significant enabler of this growth is the emergence of single-use bioprocessing, which has revolutionized how biopharmaceuticals are manufactured.

In this blog, we will explore the single-use bioprocessing market, its driving factors, key trends, and challenges shaping the future of the industry.

Market Overview and Growth Drivers

1. Rising Demand for Biopharmaceuticals

The increasing prevalence of chronic diseases, coupled with the global demand for vaccines and advanced therapies, has driven the need for cost-effective and scalable manufacturing solutions. Single-use technologies meet these requirements by enabling faster production cycles and reducing contamination risks.

2. Flexibility and Cost Savings

Traditional stainless-steel systems require significant capital investment, cleaning validation, and downtime between production runs. In contrast, single-use systems provide greater flexibility for small-scale and multiproduct manufacturing, reducing operational costs.

3. Advancements in Cell and Gene Therapy

The rapid progress in cell and gene therapy has fueled the adoption of single-use technologies, as they are well-suited for small-batch, high-value products.

4. Sustainability Concerns

While single-use systems generate plastic waste, they consume less water and energy compared to traditional systems. As manufacturers explore recycling initiatives, the environmental footprint of SUS is being addressed.

Key Trends in the Single-use Bioprocessing Industry

1. Integration of Automation and Digitalization

Smart bioprocessing solutions with integrated automation and data analytics are becoming increasingly popular. These systems improve process monitoring, enhance scalability, and reduce human error.

2. Expansion of Biotech Startups

Startups and small-scale biotech firms are leveraging single-use systems to enter the market with minimal capital expenditure. The modular design of SUS enables quick scaling up or down, depending on production needs.

3. Emergence of Modular Biomanufacturing Facilities

The rise of modular facilities using single-use technologies is revolutionizing manufacturing, allowing for rapid deployment and easy adaptation to new product pipelines.

4. Geographical Expansion

While the U.S. and Europe remain dominant markets, emerging economies in Asia-Pacific are witnessing rapid adoption of single-use bioprocessing, driven by investments in biopharma infrastructure and government initiatives to promote local manufacturing.

Challenges in the Industry

Despite its advantages, the single-use bioprocessing market faces several challenges:

Plastic Waste Management: The environmental impact of disposable components remains a concern. Manufacturers are exploring recycling solutions and bio-based plastics to address sustainability issues.

Supply Chain Disruptions: The growing demand for single-use components has occasionally led to supply chain bottlenecks, particularly during the COVID-19 pandemic.

Standardization and Scalability: Lack of standardization across suppliers can complicate integration and scalability for biomanufacturers.

Cost of Raw Materials: Rising prices of polymer-based materials used in SUS can impact profitability.

Future Outlook

The single-use bioprocessing market is set to continue its upward trajectory, driven by technological advancements, increasing investments in biopharmaceutical R&D, and the growing adoption of flexible manufacturing solutions. As sustainability challenges are addressed and global adoption expands, single-use technologies will remain a cornerstone of biopharmaceutical innovation.

Conclusion

Single-use bioprocessing has redefined the landscape of biopharmaceutical manufacturing, offering unparalleled efficiency, flexibility, and cost savings. As the market grows, collaboration between manufacturers, suppliers, and regulatory bodies will be crucial to address challenges and unlock the full potential of this transformative technology.

For More information Visit Single-use bioprocessing market

[nahoo883]

Meet the Texas startup that wants to decarbonize the chemical industry

Solugen, a startup that has set itself up with no less lofty a goal than the decarbonization of a massive chunk of the petrochemical industry, may be the first legitimate multi-million dollar company to start out in a meth lab.

When company co-founders Gaurab Chakrabarti and Sean Hunt began hunting for a lab to test their process for enzymatically manufacturing hydrogen peroxide they only had a small $10,000 grant from MIT — which was supposed to pay their salaries and cover rent and lab equipment. 

Chakrabarti, who now jokingly calls himself “the Heisenberg of hydrogen peroxide” says that the lab spaces they looked at initially were all too pricey, so through a friend of a friend of a friend, he and Hunt wound up leasing lab space in a facility by the Houston airport for $150 per month.

It was there among the burners and round-bottomed flasks that Hunt and Chakrabarti refined their manufacturing process — using fermentation based on Solugen’s proprietary enzyme made from genetically modified yeast cells to produce hydrogen peroxide. 

“In 2016 I went to visit Solugen’s headquarters in Houston, They were subleasing a small part of a bigger lab and it was one of the sketchiest labs I’d seen, but the Solugen founders liked it because the rent was low” recalls Solugen seed investor, Seth Bannon, a founding partner with the investment firm Fifty Years. “Sean and Gaurab were incredibly impressive. They had their prototype reactor up and running and were already selling 100% of its capacity, so we invested.”

Creating a process that can make thousands of tons of chemicals — without relying on petroleum — would be a hugely important step in the fight against global climate change. And Solugen says it has done exactly that — while getting the chemical industry to subsidize its development.

The chemicals industry is responsible for 10% of global energy consumption and 30% of industrial energy demand, while also contributing 20% of all industrial greenhouse gas emissions, according to the website Global Efficiency Intelligence.

As the world begins to confront the effects of global climate change, curbing emissions from industry will be critically important to ensuring that the world is not irrevocably and catastrophically changed by human activity.

As columnist Ramez Naam wrote in TechCrunch:

Our hardest climate problems – the ones that are both large and lack obvious solutions – are agriculture (and deforestation – its major side effect) and industry. Together these are 45% of global carbon emissions. And solutions are scarce.

Agriculture and land use account for 24% of all human emissions. That’s nearly as much as electricity, and twice as much all the world’s passenger cars combined.

Industry – steel, cement, and manufacturing – account for 21% of human emissions – one and a half times as much as all the world’s cars, trucks, ships, trains, and planes combined.

Image courtesy Global Efficiency Intelligence

Greenhouse gas emissions are only one of the dangers associated with the petrochemical industry’s approach to production. The processes by which chemicals are made are also incredibly volatile, and the work is dangerous for both employees and the communities in which these plants operate.

Last week, a chemical plant explosion has led to one of the worst fires in the city’s history. Firefighters in the city spent six days trying to contain a chemical fire that has burned 11 storage tanks managed by Intercontinental Terminals Company.

“They’re moving chemicals exposed to the environment, and those chemicals are not designed to be transported in that way,” Francisco Sanchez, the county’s deputy emergency emergency management coordinator told The Houston Chronicle. 

Man in protective workwear with Caution cordon tape (Courtesy Getty Images)

By contrast, Solugen’s process is only a little more dangerous than brewing beer.

In the years since Bannon came to visit the company in its first lab, Solugen has built a working production plant capable of making enough hydrogen peroxide to bring in tens of millions of dollars in revenue for the company.

In addition to its current mobile manufacturing facility, a skid mounted 1,000 square foot mini plant, Solugen is using $13.5 million in new financing from investors to build a new, 2,500 modular facility which will produce 5,000 tons of hydrogen peroxide per year. 

That new money came from the investment fund Founders Fund (co-founded by the controversial libertarian investor, Peter Thiel), Fifty Years, and Y Combinator.

Solugen’s secret sauce is its ability to create oxidase enzymes cheaply that can be combined with simple sugars to make oxidation chemicals — which account for roughly half of the $4.3 trillion dollar global chemical industry.

The companies bioreactors have been specifically designed for the chemicals it makes, but the real innovation is looking at enzymes as a tool for oxidation chemistries.

Companies are now able to engineer these enzymes thanks to advances on computational biology and the newfound ability of biochemists to engineer DNA, Chakrabarti says.

Solugen uses CRISPR gene editing technologies to modify yeast cells. It has identified a certain transcription factor which acts like an accelerant to producing the enzyme that Solugen’s process requires. Messenger ribonucleic acid overwhelms most of the typical processes if a celll to force the cell to dedicate most of its function toward enzyme production. The company then uses a contract research organization to cheaply make the enzyme at scale.

Companies also have driven down the cost of manufacturing these specialty enzymes. “The revolution is the commoditization of biomanufacturing specifically enzyme production,” he says. “Instead of our enzymes costing $1,000 per kg… It’s $1 to $10 per kg.”

Once Solugen proves that the new facility can work, the only issue is scaling, according to Chakrabarti. “We use enzyme technologies to create chemical mini-mills [and] each mini-mill can do 5,000 tons of products,” says Chakrabarti.

A typical chemical [lant has a production capacity of 50,000 tons, but the Solugen process is orders of magnitude more inexpensive, says Chakrabarti. That allows the company to build out a network of smaller plants profitably. “These are huge industries where we can make cheaper products,”he says.

And for every ton of product that Solugen makes and sells, it’s the equivalent of removing six tons of carbon from the atmosphere, Chakrabarti says.

Oil and gas companies have already signed contracts and are ordering the company’s products to the tune of several million in sales.

“It’s a nice way of funding us and funding the oil and gas industry’s demise,” says Chakrabarti of the company’s sales to its initial customers, “They give us money and allow us to go after other chemistries that would have been petroleum based… Our ultimate goal is to wipe them out.”

  from TechCrunch https://ift.tt/2FyoLzy via IFTTT from Blogger https://ift.tt/2uqxOfl via IFTTT

[rootsanalysis]

Modular Facilities in Pharmaceutical and Biotechnology Market, 2021-2030

To order this 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html

 Key Inclusions

§  A review of the market landscape of modular facilities along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), geographical coverage, GMP compliance construction and type of industry served (pharmaceutical, biotechnology or others). It also includes details related to certifications obtained and COVID-19 related initiatives undertaken by modular service providers.

§  A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), type of industry served (pharmaceutical, biotechnology or others), type of modular cleanrooms (softwall and hardwall), type of modular cleanroom components (air handling units / HVAC system, fan filter units, laminar flow units, air showers, pass throughs, cleanroom furniture / furnishings, plumbing / piping, lighting / electricals). It also includes details related to regulatory approvals and certifications.

§  An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021 (till January), covering facility construction agreements, cleanroom construction agreements, service alliances, service agreements and other relevant types of deals.

§  An analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. We have provided a case study on JHL Biotech's KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China. It also includes information on modular projects received by key pharma / biotech players based on location, type and area of facility.

§  An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players, along with information on their number of facilities, type of facility, purpose, investments made in modular projects, area of facility and location of headquarters.

§  Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to modular facility- focused services, modular projects, recent developments and an informed future outlook.

§  A review of emerging trends, including the combination of single-use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.

§  A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs and the anticipated increase in the adoption of modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs. It also highlights trends, such as expansion of existing facilities and adoption of modular facilities by emerging start-ups and small companies.

 The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

·         Type of Modular Construct 

§  Hybrid Skid

§  Plug-and-Play

§  Skid-Mounted

§  Truckable

§  Others

§  Type of Construction Component

§  Base Building

§  Electrical System

§  Mechanical System

§  Process Equipment

§  Process Piping

§  Process Utilities

§  Other Components

§  Purpose of Facility

§  Aseptic Filling

§  Manufacturing

§  Research and Development

§  Others

§  Facility Area

§  Very Small

§  Small

§  Mid-Sized

§  Large

§  Very Large

§  Scale of Operation

§  Clinical

§  Commercial

§  Type of Industry

§  Pharmaceutical                    

§  Biotechnology

§  Type of Product

§  Biosimilars              

§  Cell and Gene Therapies

§  Monoclonal Antibodies

§  Vaccines

§  Other Products

§  Type of Facility

§  New Facility

§  Facility Expansions

§  Key Geographical Regions

§  North America                    

§  Europe

§  Asia

§  Middle East and North Africa

§  Latin America

§  Rest of the World

 To Request Sample Pages - https://www.rootsanalysis.com/reports/178/request-sample.html

 Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)

§  François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)

§  Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)

§  Pär Almhem (President, Modwave)

§  Sulogna Roy (Ex Sales Manager, Zeton)

§  Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

 Key Questions Answered

§  Who are the key service providers engaged in domain of modular construction? What are the current trends fueling the adoption of modular construction solutions in the pharma / biotech industries?

§  Which key regions are targeted by pharma / biotech companies for expanding their existing facilities and capabilities?

§  What type of product lines are actively supported by integrated modular solutions in facility design and construction?

§  What are the recent initiatives undertaken by modular manufacturers in order to overcome the challenges related to the COVID-19 pandemic? 

§  Which regions are the current hubs for modular construction service providers?

§  Which partnership models are most commonly adopted by stakeholders engaged in this industry?

§  How is the current and future opportunity likely to be distributed across key market segments?

 Download Free Insights now - https://www.rootsanalysis.com/reports/178/free-insights.html

 You may also be interested in the following titles:

1.       Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030

2.       Biopharmaceutical CROs Market, 2021-2030

3.     Continuous Manufacturing Equipment Providers Market, 2021-2030

4.     DNA-Encoded Libraries: Platforms and Services Market

5.       Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

 Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

[toomanysinks]

Meet the Texas startup that wants to decarbonize the chemical industry

Solugen, a startup that has set itself up with no less lofty a goal than the decarbonization of a massive chunk of the petrochemical industry, may be the first legitimate multi-million dollar company to start out in a meth lab.

When company co-founders Gaurab Chakrabarti and Sean Hunt began hunting for a lab to test their process for enzymatically manufacturing hydrogen peroxide they only had a small $10,000 grant from MIT — which was supposed to pay their salaries and cover rent and lab equipment. 

Chakrabarti, who now jokingly calls himself “the Heisenberg of hydrogen peroxide” says that the lab spaces they looked at initially were all too pricey, so through a friend of a friend of a friend, he and Hunt wound up leasing lab space in a facility by the Houston airport for $150 per month.

It was there among the burners and round-bottomed flasks that Hunt and Chakrabarti refined their manufacturing process — using fermentation based on Solugen’s proprietary enzyme made from genetically modified yeast cells to produce hydrogen peroxide. 

“In 2016 I went to visit Solugen’s headquarters in Houston, They were subleasing a small part of a bigger lab and it was one of the sketchiest labs I’d seen, but the Solugen founders liked it because the rent was low” recalls Solugen seed investor, Seth Bannon, a founding partner with the investment firm Fifty Years. “Sean and Gaurab were incredibly impressive. They had their prototype reactor up and running and were already selling 100% of its capacity, so we invested.”

Creating a process that can make thousands of tons of chemicals — without relying on petroleum — would be a hugely important step in the fight against global climate change. And Solugen says it has done exactly that — while getting the chemical industry to subsidize its development.

The chemicals industry is responsible for 10% of global energy consumption and 30% of industrial energy demand, while also contributing 20% of all industrial greenhouse gas emissions, according to the website Global Efficiency Intelligence.

As the world begins to confront the effects of global climate change, curbing emissions from industry will be critically important to ensuring that the world is not irrevocably and catastrophically changed by human activity.

As columnist Ramez Naam wrote in TechCrunch:

Our hardest climate problems – the ones that are both large and lack obvious solutions – are agriculture (and deforestation – its major side effect) and industry. Together these are 45% of global carbon emissions. And solutions are scarce.

Agriculture and land use account for 24% of all human emissions. That’s nearly as much as electricity, and twice as much all the world’s passenger cars combined.

Industry – steel, cement, and manufacturing – account for 21% of human emissions – one and a half times as much as all the world’s cars, trucks, ships, trains, and planes combined.

Image courtesy Global Efficiency Intelligence

Greenhouse gas emissions are only one of the dangers associated with the petrochemical industry’s approach to production. The processes by which chemicals are made are also incredibly volatile, and the work is dangerous for both employees and the communities in which these plants operate.

Last week, a chemical plant explosion has led to one of the worst fires in the city’s history. Firefighters in the city spent six days trying to contain a chemical fire that has burned 11 storage tanks managed by Intercontinental Terminals Company.

“They’re moving chemicals exposed to the environment, and those chemicals are not designed to be transported in that way,” Francisco Sanchez, the county’s deputy emergency emergency management coordinator told The Houston Chronicle. 

Man in protective workwear with Caution cordon tape (Courtesy Getty Images)

By contrast, Solugen’s process is only a little more dangerous than brewing beer.

In the years since Bannon came to visit the company in its first lab, Solugen has built a working production plant capable of making enough hydrogen peroxide to bring in tens of millions of dollars in revenue for the company.

In addition to its current mobile manufacturing facility, a skid mounted 1,000 square foot mini plant, Solugen is using $13.5 million in new financing from investors to build a new, 2,500 modular facility which will produce 5,000 tons of hydrogen peroxide per year. 

That new money came from the investment fund Founders Fund (co-founded by the controversial libertarian investor, Peter Thiel), Fifty Years, and Y Combinator.

Solugen’s secret sauce is its ability to create oxidase enzymes cheaply that can be combined with simple sugars to make oxidation chemicals — which account for roughly half of the $4.3 trillion dollar global chemical industry.

The companies bioreactors have been specifically designed for the chemicals it makes, but the real innovation is looking at enzymes as a tool for oxidation chemistries.

Companies are now able to engineer these enzymes thanks to advances on computational biology and the newfound ability of biochemists to engineer DNA, Chakrabarti says.

Solugen uses CRISPR gene editing technologies to modify yeast cells. It has identified a certain transcription factor which acts like an accelerant to producing the enzyme that Solugen’s process requires. Messenger ribonucleic acid overwhelms most of the typical processes if a celll to force the cell to dedicate most of its function toward enzyme production. The company then uses a contract research organization to cheaply make the enzyme at scale.

Companies also have driven down the cost of manufacturing these specialty enzymes. “The revolution is the commoditization of biomanufacturing specifically enzyme production,” he says. “Instead of our enzymes costing $1,000 per kg… It’s $1 to $10 per kg.”

Once Solugen proves that the new facility can work, the only issue is scaling, according to Chakrabarti. “We use enzyme technologies to create chemical mini-mills [and] each mini-mill can do 5,000 tons of products,” says Chakrabarti.

A typical chemical [lant has a production capacity of 50,000 tons, but the Solugen process is orders of magnitude more inexpensive, says Chakrabarti. That allows the company to build out a network of smaller plants profitably. “These are huge industries where we can make cheaper products,”he says.

And for every ton of product that Solugen makes and sells, it’s the equivalent of removing six tons of carbon from the atmosphere, Chakrabarti says.

Oil and gas companies have already signed contracts and are ordering the company’s products to the tune of several million in sales.

“It’s a nice way of funding us and funding the oil and gas industry’s demise,” says Chakrabarti of the company’s sales to its initial customers, “They give us money and allow us to go after other chemistries that would have been petroleum based… Our ultimate goal is to wipe them out.”

  source https://techcrunch.com/2019/03/24/meet-the-texas-startup-that-wants-to-decarbonize-the-chemical-industry/

[fmservers]

Meet the Texas startup that wants to decarbonize the chemical industry

Solugen, a startup that has set itself up with no less lofty a goal than the decarbonization of a massive chunk of the petrochemical industry, may be the first legitimate multi-million dollar company to start out in a meth lab.

When company co-founders Gaurab Chakrabarti and Sean Hunt began hunting for a lab to test their process for enzymatically manufacturing hydrogen peroxide they only had a small $10,000 grant from MIT — which was supposed to pay their salaries and cover rent and lab equipment. 

Chakrabarti, who now jokingly calls himself “the Heisenberg of hydrogen peroxide” says that the lab spaces they looked at initially were all too pricey, so through a friend of a friend of a friend, he and Hunt wound up leasing lab space in a facility by the Houston airport for $150 per month.

It was there among the burners and round-bottomed flasks that Hunt and Chakrabarti refined their manufacturing process — using fermentation based on Solugen’s proprietary enzyme made from genetically modified yeast cells to produce hydrogen peroxide. 

“In 2016 I went to visit Solugen’s headquarters in Houston, They were subleasing a small part of a bigger lab and it was one of the sketchiest labs I’d seen, but the Solugen founders liked it because the rent was low” recalls Solugen seed investor, Seth Bannon, a founding partner with the investment firm Fifty Years. “Sean and Gaurab were incredibly impressive. They had their prototype reactor up and running and were already selling 100% of its capacity, so we invested.”

Creating a process that can make thousands of tons of chemicals — without relying on petroleum — would be a hugely important step in the fight against global climate change. And Solugen says it has done exactly that — while getting the chemical industry to subsidize its development.

The chemicals industry is responsible for 10% of global energy consumption and 30% of industrial energy demand, while also contributing 20% of all industrial greenhouse gas emissions, according to the website Global Efficiency Intelligence.

As the world begins to confront the effects of global climate change, curbing emissions from industry will be critically important to ensuring that the world is not irrevocably and catastrophically changed by human activity.

As columnist Ramez Naam wrote in TechCrunch:

Our hardest climate problems – the ones that are both large and lack obvious solutions – are agriculture (and deforestation – its major side effect) and industry. Together these are 45% of global carbon emissions. And solutions are scarce.

Agriculture and land use account for 24% of all human emissions. That’s nearly as much as electricity, and twice as much all the world’s passenger cars combined.

Industry – steel, cement, and manufacturing – account for 21% of human emissions – one and a half times as much as all the world’s cars, trucks, ships, trains, and planes combined.

Image courtesy Global Efficiency Intelligence

Greenhouse gas emissions are only one of the dangers associated with the petrochemical industry’s approach to production. The processes by which chemicals are made are also incredibly volatile, and the work is dangerous for both employees and the communities in which these plants operate.

Last week, a chemical plant explosion has led to one of the worst fires in the city’s history. Firefighters in the city spent six days trying to contain a chemical fire that has burned 11 storage tanks managed by Intercontinental Terminals Company.

“They’re moving chemicals exposed to the environment, and those chemicals are not designed to be transported in that way,” Francisco Sanchez, the county’s deputy emergency emergency management coordinator told The Houston Chronicle. 

Man in protective workwear with Caution cordon tape (Courtesy Getty Images)

By contrast, Solugen’s process is only a little more dangerous than brewing beer.

In the years since Bannon came to visit the company in its first lab, Solugen has built a working production plant capable of making enough hydrogen peroxide to bring in tens of millions of dollars in revenue for the company.

In addition to its current mobile manufacturing facility, a skid mounted 1,000 square foot mini plant, Solugen is using $13.5 million in new financing from investors to build a new, 2,500 modular facility which will produce 5,000 tons of hydrogen peroxide per year. 

That new money came from the investment fund Founders Fund (co-founded by the controversial libertarian investor, Peter Thiel), Fifty Years, and Y Combinator.

Solugen’s secret sauce is its ability to create oxidase enzymes cheaply that can be combined with simple sugars to make oxidation chemicals — which account for roughly half of the $4.3 trillion dollar global chemical industry.

The companies bioreactors have been specifically designed fir the chemicals it makes, but the real innovation is looking at enzymes as a tool for oxidation chemistries.

Companies are now able to engineer these enzymes thanks to advances on computational biology and the newfound ability of biochemists to engineer DNA, Chakrabarti says.

Solugen uses CRISPR gene editing technologies to modify yeast cells. It has identified a certain transcription factor which acts like an accelerant to producing the enzyme that Solugen’s process requires. Messenger ribonucleic acid overwhelms most of the typical processes if a celll to force the cell to dedicate most of its function toward enzyme production. The company then uses a contract research organization to cheaply make the enzyme at scale.

Companies also have driven down the cost of manufacturing these specialty enzymes. “The revolution is the commoditization of biomanufacturing specifically enzyme production,” he says. “Instead of our enzymes costing $1,000 per kg… It’s $1 to $10 per kg.”

Once Solugen proves that the new facility can work, the only issue is scaling, according to Chakrabarti. “We use enzyme technologies to create chemical mini-mills [and] each mini-mill can do 5,000 tons of products,” says Chakrabarti.

A typical chemical [lant has a production capacity of 50,000 tons, but the Solugen process is orders of magnitude more inexpensive, says Chakrabarti. That allows the company to build out a network of smaller plants profitably. “These are huge industries where we can make cheaper products,”he says.

And for every ton of product that Solugen makes and sells, it’s the equivalent of removing six tons of carbon from the atmosphere, Chakrabarti says.

Oil and gas companies have already signed contracts and are ordering the company’s products to the tune of several million in sales.

“It’s a nice way of funding us and funding the oil and gas industry’s demise,” says Chakrabarti of the company’s sales to its initial customers, “They give us money and allow us to go after other chemistries that would have been petroleum based… Our ultimate goal is to wipe them out.”

  Via Jonathan Shieber https://techcrunch.com